Literature DB >> 15140272

Meningiomas: updating basic science, management, and outcome.

Katharine J Drummond1, Jay-Jiguang Zhu, Peter McL Black.   

Abstract

BACKGROUND: Meningiomas are biologically complex and clinically and surgically challenging. These features, combined with the rewarding potential for cure, make them of great interest to neurologists, neurosurgeons, and neuroscientists alike. REVIEW
SUMMARY: Initially, we review the clinical context of meningiomas, particularly recent changes in histopathological classification, diagnosis, and neuroimaging. Secondly, the underlying basic science as it has evolved over the last decades is summarized. The status of areas recently of intense interest, such as steroid hormone receptors and oncogenic viruses is described. Additionally, emerging areas of great promise, such as cytogenetics and molecular biology are presented. Lastly, we describe recent advances in management. In particular, skull-base surgery, image-guided surgery, and advances in radiotherapy are emphasized. The possible impact of basic research on management and outcome is also outlined.
CONCLUSIONS: Although usually benign and amenable to cure, meningiomas still present significant diagnostic and treatment challenges. Advances in basic science, surgery, and adjuvant therapy are widening the potential for safe, effective, evidence-based management leading to even better outcomes

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140272     DOI: 10.1097/01.nrl.0000126588.14216.f3

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  9 in total

Review 1.  A review of image-guided radiotherapy.

Authors:  George T Y Chen; Gregory C Sharp; Shinichiro Mori
Journal:  Radiol Phys Technol       Date:  2008-12-16

2.  Demographic profile of patients diagnosed with intracranial meningiomas in two academic hospitals in Johannesburg, South Africa: a 12-month prospective study.

Authors:  Kaunda Ibebuike; John Ouma
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

Review 3.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

4.  Treatment-related secondary cancer in malignant meningiomas: a population-based study.

Authors:  Xuhui Bao; Lanfang Cao; Hailan Piao; Liyi Xie
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-08       Impact factor: 4.553

5.  The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells.

Authors:  Huda H Al-Khalaf; Boleslaw Lach; Ayman Allam; Ahmed AlKhani; Salman A Alrokayan; Abdelilah Aboussekhra
Journal:  J Neurooncol       Date:  2007-01-24       Impact factor: 4.130

6.  Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.

Authors:  L De Marinis; A Fusco; A Bianchi; G Aimaretti; M R Ambrosio; C Scaroni; S Cannavo; C Di Somma; F Mantero; E C degli Uberti; G Giordano; E Ghigo
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

Review 7.  FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients.

Authors:  D Zlotnick; S N Kalkanis; A Quinones-Hinojosa; K Chung; M E Linskey; R L Jensen; F DeMonte; F G Barker; C A Racine; M S Berger; P M Black; M Cusimano; L N Sekhar; A Parsa; M Aghi; Michael W McDermott
Journal:  J Neurooncol       Date:  2010-09-18       Impact factor: 4.130

8.  Gamma knife radiosurgery of meningiomas involving the foramen magnum.

Authors:  Robert M Starke; James H Nguyen; Davis L Reames; Jessica Rainey; Jason P Sheehan
Journal:  J Craniovertebr Junction Spine       Date:  2010-01

9.  Meningioma surgery in younger and older adults: patient profile and surgical outcomes.

Authors:  K Mariam Slot; Jocelyne V M Peters; W Peter Vandertop; Dagmar Verbaan; Saskia M Peerdeman
Journal:  Eur Geriatr Med       Date:  2017-12-21       Impact factor: 1.710

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.